This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Camzyos came up short in a phase 3 trial weighing its use in patients with non-o...
During its quarterly earnings report, executives at Johnson & Johnson said they ...
Critiques of the vaccine injury reporting system have long been part of Kennedy’...
After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuti...
TUESDAY, April 15, 2025 -- The new International League Against Epilepsy (ILAE)...
TUESDAY, April 15, 2025 -- Air pollution is associated with domain-specific imp...
TUESDAY, April 15, 2025 -- Exposure-response curves reveal the impacts of dayti...
TUESDAY, April 15, 2025 -- For adults with sickle cell disease (SCD), C-reactiv...
TUESDAY, April 15, 2025 -- The rate of emergency department visits for adverse ...
TUESDAY, April 15, 2025 -- After approval, tirzepatide dispensations increased ...
TUESDAY, April 15, 2025 -- The incidence of neonatal herpes simplex virus (nHSV...
Critiques of the vaccine injury reporting system have long been part of Kennedy’...
Merck will create oral versions of its peptides using Cyprumed's drug delivery t...
Medical devices like J&J’s surgical robots have already been hit by the new US c...
CenExel is the latest CRO to change ownership hands. Boston-based private equity...
The head of Mass General Brigham said officials at the Harvard-affiliated health...
The Trump administration is freezing more than $2.2 billion in funding to Harvar...
Even as tariffs start to impact its medtech business, Johnson & Johnson is lifti...
Sanofi has said “deal” to Chrissy Teigen. The model, cookbook author and “Deal o...
While J&J expects tariffs will cost it $400 million this year, the company maint...
Human medicines European public assessment report (EPAR): Zefylti, filgrastim, D...
The companies said they will work together to train artificial intelligence algo...
Camzyos came up short in a phase 3 trial weighing its use in patients with non-o...